As of August 19, the People's Bank of China has maintained a "zero injection" volume for its seven-day reverse repurchase operations for seven consecutive trading days, drawing widespread market attention. Taking into account the central bank's recent series of liquidity operations, the prevailing trend in market interest rates, and the broader regulatory approach, I believe that this string of zero injections does not signal a liquidity squeeze. Rather, it reflects the central bank's precise, demand-driven liquidity management in response to evolving market supply and demand dynamics.

Looking at the operational logic, the People's Bank of China has explicitly stated in its recent open market operation announcements that it determines the day's seven-day reverse repo volume of zero "based on the demand from primary dealers in open market operations." Consequently, the direct cause of the zero injection is weakened demand from these primary dealers. Currently, the seven-day reverse repo operates under a fixed-rate, quantity-bidding mechanism, meaning the operational scale is not unilaterally preset by the central bank but is instead determined by the genuine funding needs of financial institutions. Since mid-August, market rates such as DR001 and DR007 have consistently traded below the policy rate—set at 1.4% for the seven-day reverse repo—indicating that liquidity supply in the interbank market is relatively ample. As a result, financial institutions' willingness to borrow seven-day funds from the central bank has naturally declined. The zero injection is a market outcome of self-balancing supply and demand, not a deliberate policy move by the central bank to withdraw liquidity.

It is important to note that the zero injection of seven-day reverse repos does not imply a complete suspension of open market operations. To address temporary funding fluctuations caused by tax payment peaks and government bond issuance, the People's Bank of China has deployed overnight reverse repos as a complementary tool, announcing operational arrangements in advance with a daily cap of 600 billion yuan. This allows for flexible adjustment of injection volumes based on actual funding gaps, thereby smoothing short-term liquidity volatility. Furthermore, the central bank conducted a 500-billion-yuan three-month outright reverse repo on August 5, resulting in a net injection of 200 billion yuan after offsetting maturing operations, and followed up with an equal-value rollover of six-month outright reverse repos on August 14. The flexible use of overnight reverse repos and the increased injection of medium- to long-term funds clearly demonstrate the central bank's commitment to safeguarding liquidity.

At the same time, this operational model of combining short- and long-term tools with precise, on-demand injections also helps prevent the accumulation of excessive liquidity that could fuel fund idling or arbitrage risks, fully reflecting the central bank's refined approach to liquidity management. In summary, the market should not overinterpret the consecutive zero injections in seven-day reverse repos, nor should it harbor concerns about liquidity tightening. Looking ahead, the People's Bank of China will continue to employ and adjust a comprehensive set of monetary policy tools to maintain ample liquidity, fostering a suitable monetary and financial environment for the real economy and providing solid financial support for the sustained recovery and improvement of the macroeconomy.